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Objective: To determine whether the serum β-human chorionic gonadotropin (hCG) profile following preimplantation genetic diagnosis (PGD) 
is lower than that of intracytoplasmic sperm injection (ICSI) cycles. 
Methods: A total of 129 PGD cycles and 1,161 age-matched ICSI cycles, which resulted in pregnancy (serum β-hCG≥5 mIU/mL) on post-ovu-
lation day (POD) 12 were included. We compared the mean serum β-hCG levels on POD 12, 14, 21, and 28, doubling time of serum hCG, and 
created a cut-off value for predicting a singleton pregnancy in each group. 
Results: The mean serum β-hCG concentration of the PGD group was significantly lower than that of the control group on POD 12, 14, and 21. 
The doubling time of serum β-hCG at each time interval showed no significant difference. The cut-off-value of serum β-hCG for predicting a 
single viable pregnancy was 32.5 mIU/mL on POD 12 and 113.5 mIU/mL on POD 14 for the PGD group, which was lower than that for the con-
trol group.
Conclusion: Blastomere biopsy may decrease the β-hCG-producing activity of the trophoblasts, especially in early pregnancy. Setting a lower 
cut-off value of serum β-hCG for predicting pregnancy outcomes in PGD may be needed. 
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Introduction
Human chorionic gonadotropin (hCG) can be detected in the ma-
ternal serum as early as eight days after conception. Serum β-hCG 
can be detected in 5% of cycles 8 days after the preovulatory lutein-
izing hormone surge, in 16% after 9 days, in 53% after 10 days, and in 
100% of all cycles after day 11 [1]. During embryo development, β- 
hCG mRNAs have been identified in a single blastomere in a 4-cell 
stage embryo, but not in a 2-cell stage embryo [2]. In human blasto-
cysts, β-hCG mRNA is differentially expressed mainly in trophecto-
derm cells, with very little or none present in the inner cell mass (ICM) 
[3]. Produced and secreted by syncytiotrophoblasts, its serum level 
represents the trophoblastic mass [4]. The amount of β-hCG in cul-
ture media secreted by the blastocysts after biopsy is inversely pro-
portional to the number of trophectoderm cells removed [5]. How-
ever, there are no studies on serum β-hCG levels in early pregnancy 
after a preimplantation genetic diagnosis (PGD) procedure, especially 
after blastomere biopsy. Removing one or two blastomeres from the 
eight cell stage embryo is one of the techniques of PGD and, after 
this procedure, according to one study, the total number of cells and 
the number of both trophectoderm (TE) and ICM cells of the biop-
sied embryos at the blastocyst stage were reduced, although the ra-
tio of ICM to TE cells was maintained in both 7/8 and 6/8 biopsied 
embryos [6]. 
It is beneficial for the patient, her family, and the clinician to have a 
reliable prognostic marker of pregnancy outcomes at the early stage. 
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A single early serum β-hCG test or serial serum β-hCG determinations 
have been used to monitor early pregnancy outcomes, with serial 
measurements known to have greater predictive accuracy [7]. Low 
levels of serum β-hCG in early pregnancy have been reported as a 
predictor of poor pregnancy outcomes, including chemical pregnan-
cy, ectopic pregnancy, and miscarriages [7-10]. Undergoing IVF until 
pregnancy is confirmed can be very stressful, but PGD can be even 
more stressful because of the fear of an abnormal pregnancy or re-
peated pregnancy loss. 
Decreased trophectoderm cell numbers after biopsy may influence 
the secretion of β-hCG from the syncytiotrophoblasts and the implan-
tation potential in early placentation. Thus, we hypothesized that the 
serum β-hCG profile could be adversely affected after blastomere bi-
opsy in PGD cycles. The aim of this study was to evaluate whether 
blastomere biopsies affect early serum β-hCG concentration in preg-
nancies following PGD. In addition, we attempted to determine if a 
different cut-off value of serum β-hCG in PGD is needed for predic-
tion of a successful pregnancy.
Methods
1.	Study	design	and	patients
The study was designed as a retrospective age-matched case-con-
trol study. The records of all patients of the IVF Clinic of Cheil General 
Hospital during January 2000 to May 2006 were retrospectively re-
viewed. This study was approved by our institutional review board.
One hundred twenty-nine pregnancies achieved by PGD with an 
initial serum β-hCG concentration≥5 mIU/mL on post-ovulation day 
(POD) 12 were recruited. The main indications of PGD were structural 
chromosomal abnormalities: reciprocal translocation (63.6%), Rob-
ertsonian translocation (14.0%), and inversion (4.7%). Other indica-
tions were single gene disorder (7.0%), aneuploidy screening (7.8%), 
and sex chromosomal abnormality. A randomly selected group of 
1,161 age-matched patients who underwent intracyto plasmic sperm 
injection (ICSI) during the same period with an initial serum β-hCG 
concentration≥5 mIU/mL POD were selected as the control group. 
The most frequent indications for the control group were male factor 
(35.1%), tubal factor (22.6%), and endometriosis (18.0%). The other 
indications included ovulatory factor (7.9%), and advanced maternal 
age (1.1%), as well as unexplained reasons (9.1%). The reasons the 
patients in this study underwent either procedure are summarized in 
Table 1.
We excluded those patients with factors that may contribute to ear-
ly implantation, such as azoospermia, adenomyosis, uterine anomaly, 
uterine synechiae, and infection. Pregnancies resulting from cryopre-
servation and donor transfer were also excluded. 
2.	Treatment	protocols	and	clinical	procedures
Ovarian stimulation was performed using a GnRH agonist or antag-
onist, recombinant FSH, or hMG. Following ovarian stimulation, folli-
cles were aspirated and fertilized by ICSI. Fertilized oocytes were cul-
tured in G1.5 medium (Vitrolife, Kungsbacka, Sweden) for 3 days. For 
the PGD group, on the third day, the embryos were transferred to the 
biopsy medium (MediCult, Jyllinge, Denmark). Acidified Tyrode’s so-
lution (pH 2.3-2.4) was applied to create a small hole in the zona pel-
lucida. One or two blastomeres were biopsied by gentle aspiration 
with a polished micropipette. Zona drilling and blastomere biopsy 
were performed using a single pipette with a 30-μm inner diameter. 
The embryos were then repeatedly washed, transferred to G2.5 me-
dium, and cultured under 6% CO2 in air at 37˚C. Embryos with normal 
or balanced FISH signals, or that were unaffected after PCR, were se-
lected and transferred on the fourth or fifth day of culture. The em-
bryo transfer for the control group was performed mainly on day 3 
(range, 2-5 day). Serum β-hCG levels were measured by radioimmu-
noassay on POD 12, 14, 21, and 28. The sensitivity of the assay was 3 
mIU/mL, with intra-and interassay coefficients of variation of 1.9% 
and 2.5%, respectively. 
3.	Pregnancy	outcomes	
Clinical pregnancy was defined as the presence of a fetal heart beat 
using ultrasonography at approximately 6 to 7 weeks. Amniocentesis 
was performed to confirm the results of PGD in clinical pregnancies 
and miscarriages when samples were available.
The doubling time of serum β-hCG was defined as the number of 
days required for the serum β-hCG concentration to double and was 
calculated from the following formula: 
Doubling time (DT)=(Log2)×(Time interval in days)/Log (hCG2/
hCG1).
A viable pregnancy was defined as an ongoing pregnancy beyond 
20 weeks of gestation or delivery from a singleton pregnancy (where 
one baby was born, including stillbirths, from a pregnancy in which 
only one gestational sac and one fetal heart beat had been demon-
strated). Non-viable pregnancies included clinical abortions and ec-
Table	1. Reasons for control and PGD group assignment
Control No. (%) PGD No. (%)
Male factor 407 (35.1) Reciprocal translocation 82 (63.6)
Tubal factor 262 (22.6) Robertsonian translocation 18 (14.0)
Endometriosis 209 (18.0) Inversion 6 (4.7)
Unexplained 106 (9.1) Sex chromosome abnormality 4 (3.1)
Ovulatory factor 92 (7.9) Aneuploidy screening 10 (7.8)
Advanced age 13 (1.1) Single gene disorder 9 (7.0)
Others 72 (6.2)  
Total 1,161 Total 129
PGD, preimplantation genetic diagnosis.www.eCERM.org
YJ Cho et al.     PGD and early serum β-hCG levels
33
topic and biochemical pregnancies. 
4.	Statistical	analysis
Each serum β-hCG level was analyzed after log transformation be-
cause of non-normal distribution. We compared the mean serum 
β-hCG levels and doubling times in cycles of a single gestational sac 
which resulted in delivery (including stillbirth) because of the varia-
tion of β-hCG values in multiple pregnancies. All analyses were con-
ducted using the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). A chi-
square test or t-test was used for statistical analysis and p-values< 
0.05 were considered significant. To determine the probable cut-off 
limits for serum β-hCG values for predicting successful pregnancy out-
comes in both groups, receiver operating characteristic (ROC) curves 
were generated.
Results
One hundred twenty-nine pregnancies achieved by PGD with an 
initial serum β-hCG concentration ≥5 mIU/mL on POD 12 had struc-
tural chromosomal abnormalities. The mean age of both groups was 
31.7 years (range, 25.0-42.1 years), The mean number of transferred 
embryos in the PGD group was 2.7±1.0, which was significantly low-
er than that of the control group (3.6±1.0). When outcomes were 
examined in pregnancies established by PGD or in the control group, 
the biochemical pregnancy rate, clinical abortion rate, and ectopic 
pregnancy rate showed no significant differences. Also, neonatal out-
comes, including infant weight and prematurity rates, were compa-
rable. However, the multiple pregnancy rate was significantly lower 
in the PGD group (OR, 0.551; 95% confidence interval [CI], 0.318- 
0.953; p=0.031) (Table 2). 
Figure 1 shows the regression line of the serum β-hCG profile dur-
ing early pregnancy in cycles of a single gestational sac which result-
ed in delivery in both groups. Both lines are horizontal with a lower 
level for the PGD group (95% CI of the regression line) and the lines 
do not cross, which indicates the serum β-hCG level is consistently 
lower in the PGD group in early pregnancy. 
In examining the doubling of serum levels at each time interval, the 
PGD group showed doubling at 1.31, 1.63, and 2.53 days, which was 
not significantly different from the control group (Table 3). The mean 
serum β-hCG levels in cycles which resulted in a single gestational 
sac and singleton delivery are described in Figure 2. The levels of se-
rum β-hCG on POD 12, 14, and 21 were 37.9 mIU/mL, 111.3 mIU/mL, 
and 2,225.0 mIU/mL in the PGD group and 46.9 mIU/mL, 145.4 mIU/
mL, and 3,614 mIU/mL in the control group, and the differences were 
Table	2. Baseline characteristics and obstetric outcomes of the pa-
tients
Control PGD p-value
No. of hCG positive cycles 1,161 129
Age of female 31.7±3.8 31.7±3.8 NS
Age of husband 34.7±4.6 34.3±3.9 NS
No. of embryos transferred 3.6±1.0 2.7±1.0 0.000
Day of embryo transfer 2.97±0.5 4.07±0.3 0.000
Biochemical pregnancy 183 (15.8) 25 (19.4) NS
Ectopic pregnancy 18 (1.6) 4 (3.1) NS
Heterotopic pregnancy 2 (0.2) 2 (1.6) 0.019
Clinical abortion 122 (10.2) 18 (14.0) NS
Second trimester loss 34 (2.9) 4 (3.1) NS
Delivery 802 (69.1) 78 (60.5) 0.044
   Singleton delivery 513 (64.0) 60 (76.9)
   Twin delivery 289 (36.0) 18 (23.1) 0.031
   Preterm delivery (<37 wk) 181 (22.6) 16 (20.5) NS
   Term delivery 621 (77.4) 62 (79.5) NS
Sex ratio (M/F) 1.02 0.82 NS
Birth weight (g) 
   Singleton 3,209±525 3,280±463 NS
   Twins 2,430±483 2,512±560 NS
Values are presented as mean±SD or number (%).
PGD, preimplantation genetic diagnosis; NS, not significant.
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Figure	1. The regression lines and 95% confidence intervals of β-hCG 
values in early pregnancy in women who later had viable singleton 
pregnancy and delivery after control and preimplantation genetic di-
agnosis (PGD) group. The β-hCG values were log transformed before 
regression analysis. Red line, PGD group; Blue line, control group.
Table	3. The doubling times (in days) of human chorionic gonado-
trophin (hCG) secretion for each phase of the pregnancy cycles which 
resulted in a single gestational sac and singleton delivery
Time interval
Doubling time of hCG
POD 12-14 POD 14-21 POD 21-28
Control 1.33±0.34 1.56±0.28 2.40±0.46
PGD 1.36±0.38 1.65±0.31 2.53±0.66
p-value NS NS NS
Values are presented as mean±SE. 
POD, post-oocyte retrieval day; PGD, preimplantation genetic diagnosis; NS, 
not significant.   doi: 10.5653/cerm.2011.38.1.31
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significant (p=0.023, 0.006, 0.000, respectively). However, the mean 
serum β-hCG levels on POD 28 showed no difference (p=not signifi-
cant). 
ROC curves for the mean serum β-hCG levels in cycles which result-
ed in a single gestational sac and singleton delivery were used to de-
termine the points of inflection (specificity and sensitivity) to predict 
potential viability. From the ROC curves shown in Figure 3, the POD 
14 curve is steeper and deviates to the left than the POD 12 curve, 
which implies that β-hCG concentration on POD 14 is a better predic-
tor of fetal viability than β-hCG concentration on POD 12. On POD 12, 
the control group with a cut-off level of 40.5 mIU/mL showed a sen-
sitivity of 79.6% and specificity of 76.9%. The positive predictive val-
ue (PPV) was 89.9%, while the negative predictive value (NPV) was 
59.1%. With similar sensitivity and specificity, the cut-off value of the 
PGD group was 32.5 mIU/mL, which was lower than that of the con-
trol group (sensitivity 70.4%, specificity 70.8%, PPV 80.2%, NPV 58.6%). 
On POD 14, the control group, with a cut-off level of serum β-hCG of 
113.5 mIU/mL, had a sensitivity of 81.3% and a specificity of 78.7%. 
The PPV was 91.9%, while the NPV was 60.0%. With similar sensitivity 
and specificity, the cut-off value of the PGD group was about 77.0 
mIU/mL, which was lower than that of the control group (sensitivity 
79.7%, specificity 77.3%, PPV 85.5%, NPV 69.4%). If we apply the same 
cut-off value as in the control group for PGD on POD 14, the sensitivi-
ty and NPV are only 66.2% and 59.1%. After applying the new cut-off 
value for the PGD group, the sensitivity and NPV increase to 79.3% 
and 69.4%, respectively. 
Discussion
To the best of our knowledge, no study thus far has dealt with the 
correlation of serum β-hCG profiles in early pregnancy for PGD cycles. 
We analyzed the mean serum β-hCG levels in cycles which resulted 
in a single gestational sac and singleton delivery and suggest that 
serum β-hCG in early pregnancies of a PGD group is lower than that 
in a control group. 
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Figure	2. The highest and lowest quartile mean values of serum hu-
man chorionic gonadotrophin (hCG) on POD 12, 14, 21, and 28 in the 
preimplantation genetic diagnosis (PGD) and control groups. Values 
are presented as mean±SD. NS, not significant. 
ap=0.023, 
bp=0.006, 
cp=0.000.
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Figure	3. Nonparametric receiver-operating characteristic plots of calculated day 12 (A) and 14 (B) serum β-hCG levels to distinguish between 
viable pregnancies in both groups. Red line, preimplantation genetic diagnosis group; Blue line, control group.www.eCERM.org
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We measured the serum β-hCG level from post-oocyte retrieval day 
12. It would be more reasonable to compare the serum β-hCG level 
measured based on the oocyte retrieval day than the embryo trans-
fer day, because the oocyte retrieval day is the day of initiating fertil-
ization. The actual amount of β-hCG is thought to reflect the number 
of viable trophectoderm cells producing the hormone [11]. Initially 
low β-hCG levels and a consistently long doubling time may reflect 
abnormal implantation, poor trophoblastic activity, or both [12]. Preg-
nancies with low initial β-hCG levels have previously been shown to 
have a poor prognosis in a multitude of studies [8-10,13]. In this study, 
although the initial serum β-hCG levels were low in the PGD group, 
the biochemical pregnancy rate and miscarriage rate were similar to 
those of the control group. This may indicate that once pregnancy is 
initiated, any adverse impact of PGD is undetectable, and that low 
serum β-hCG levels in PGD are not a strong predictor of an abnormal 
pregnancy outcome. Additionally, there were no significant differ-
ences in second trimester losses, preterm delivery rates, or birth wei-
ghts between the groups. In brief, the serum β-hCG concentration 
was lower in the PGD group, but the overall pregnancy outcomes of 
the two groups were quite similar.
The doubling time of β-hCG in normal pregnancies is 1.4-3.5 days 
during the first 20-30 days of gestation [14]. Abnormal pregnancies 
often have a normal doubling time early in their course and subse-
quently become aberrant. Our data indicate that the doubling times 
of both groups were in the normal gestational growth range until 
the 35th day of gestation. Since a low doubling time may reflect ab-
normal implantation or poor trophoblastic activity, this data may in-
dicate that trophoblastic activity was not reduced in PGD cycles. 
If the biopsied blastomere is destined to be the trophectoderm, the 
biopsy procedure may lead to a reduction in trophoblastic cell mass. 
Based on the fact that the amount of β-hCG secreted by the blasto-
cyst after biopsy was inversely proportional to the number of troph-
ectoderm cells removed [5], blastomere biopsy may lead to de-
creased serum β-hCG production in early pregnancy.
In PGD, the genetic diagnosis is made by the analysis of one or two 
blastomere biopsies. Apart from the reduction in cellular mass, Hardy 
et al. found that the removal of one or two cells at the 8-cell stage 
does not adversely affect the preimplantation development of biop-
sied embryos in vitro [6]. Also, there was no significant difference in 
the number of cells in blastocysts, trophectoderm, or ICM depending 
on whether one or two blastomeres were biopsied [15]. Blastomeres 
can regain the losses from a biopsy, but we did not analyze the num-
ber of cells at the moment of embryo transfer, which may be the one 
of the limitations of our study.
In our study, the PGD group produced lower β-hCG levels on tests 
at POD 12, 14, and 21 compared to the control group. A few possible 
mechanisms might explain the discrepancy observed at the time of 
each blood test. First, the observed discrepancy may have resulted 
from a difference in the rate of very early subclinical losses, since the 
average number of embryos in each transfer was greater for the con-
trol group than for the PGD group. Second, a different embryo trans-
fer day may result in a gender bias, which in turn has been suggested 
to be related to the rate at which the early embryo develops. To ad-
just for the difference of embryo transfer dates, outcomes were ex-
amined in pregnancies established by day 3 or day 5 transfers, and 
we found that the biochemical pregnancy rate and miscarriage rate 
were similar between the two groups (data not shown). Thus, the 
variability of ET days does not appear to significantly influence the 
range of β-hCG, as evaluation of the data when grouped by transfer 
day did not show significant differences. The results of the compari-
son of the mean β-hCG values between the day 5 and day 3 transfer 
groups are controversial. Papagerorgiou et al. [16] showed that there 
were no differences in the mean β-hCG levels between the two groups. 
In contrast, Zhang et al. [17] showed that initial β-hCG levels in preg-
nancies resulting from day 5 transfers were lower than those from day 
3 transfers. These differences may have resulted from other mecha-
nisms than the blastomere biopsy itself, and larger studies may be 
needed to confirm these controversial results. Third, the blastomere 
biopsy procedure in the PGD cycle might directly and adversely af-
fect the trophectoderm cell mass in the development of the embryo, 
resulting in a subtle delay or reduction in β-hCG production.
In conclusion, our results suggest that PGD may adversely affect se-
rum β-hCG levels in early pregnancy. Setting a lower cut-off value for 
predicting a successful pregnancy in PGD could be helpful in coun-
seling pregnant patients following PGD.
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